MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases

R. C. Coll, A. A. B. Robertson, J. J. Chae, S. C. Higgins, L. S. Dungan, R. Munoz-Planillo, B. G. Monks, D. E. Croker, C. E. Sutton, A. Stutz, G. Nunez, E. Latz, D. L. Kastner, K. H. G. Mills, S. L. Masters, K. Schroder, M. A. Cooper, L. A. J. O'Neill

Research output: Contribution to journalMeeting abstractpeer-review

Original languageUndefined/Unknown
JournalCytokine
DOIs
Publication statusPublished - 2014

Cite this